Piper Jaffray Initiates Coverage on Clinical Data (CLDA) with an Overweight
More News related to CLDA
- Clinical Data, Inc. to Present at Piper Jaffray Health Care Conference
- Clinical Data, Inc. Initiates Phase III Trial of Stedivaze for Cardiac Stress Testing
- Clinical Data, Inc. Establishes Scientific Advisory Board for Cardiovascular Genetics
- Trading Overview for Sequenom Inc. Issued by StockPreacher.com
- Clinical Data, Inc. Launches Genetic Test for Dilated Cardiomyopathy (DCM) at the 2009 American Heart Association Meeting
More News related to New Coverage
- Dow Jones, S&P 500 Close Today's Trading Session at Fresh 2009 Highs
- Sign of the Times: U.S. Mint Has To Temporarily Suspend Sales of One Ounce Gold Coins Due to Demand
- Crude Inventories Lower than Expected, Energy Shares Gain Ground (XOM, COP, CVX, MRO, USO, OIL)
- Gold Moves Higher on Weak Dollar, Lower Commodities, Indian Reserve Bank Talk (GLD, ABX, GG, NEM, GDX)
- Novartis (NVS) Excites Incyte (INCY) with Licensing Deal
Piper Jaffray & Co. initiates coverage on Clinical Data (Nasdaq: CLDA) with an Overweight rating. Price target $25.
Piper analyst says, "Clinical Data is on track to file an NDA for vilazodone in 1Q:10 and assuming a standard 10 month review, the drug could be approved as early as 1Q:11. We point out that the U.S. antidepression market is $12 billion and growing and that none of the market leading therapies consistently works for a majority of patients, leaving ample opportunity for new drugs. Based on its safety profile and unique mechanism, we believe U.S. vilazodone sales could top $500 million by 2017...The company also has a small but rapidly growing genetic testing business led by its FAMILION family of diagnostics for cardiac indications. Testing revenues are currently growing at a 100% annual rate and we estimate are on track to reach $14 million this year...We believe CLDA shares are poised to rise ahead of a likely vilazodone approval next year, reflecting the market potential of this asset."
To see more analyst ratings on CLDA Click Here.
Clinical Data, Inc. operates as a global biotechnology company developing early and late stage targeted therapeutics, as well as genetic and pharmacogenomic tests that detect serious diseases and help predict drug safety, tolerability, and efficacy.
Related Categories
New CoverageStocks Mentioned
+0.15Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
